Michael Alifrangis
Overview
Explore the profile of Michael Alifrangis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
2831
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lyimo E, Kulaya N, Njotto L, Kassam N, Gesase S, Malabeja A, et al.
Malar J
. 2025 Mar;
24(1):68.
PMID: 40025559
Background: Malaria, which affects over half of the world's population, is controlled through clinical interventions and vector control strategies. However, these efforts are threatened by resistance to anti-malarial drugs and...
2.
Gore-Langton G, Madanitsa M, Barsosio H, Minja D, Mosha J, Kavishe R, et al.
BMJ Public Health
. 2025 Feb;
2(2):e000501.
PMID: 40018559
Objectives: Malaria and curable sexually transmitted and reproductive tract infections (STIs/RTIs) are associated with adverse pregnancy outcomes. This study reports the prevalence and risk factors of curable STIs/RTIs, STI/RTI co-infection...
3.
Njotto L, Senyoni W, Cronie O, Alifrangis M, Stensgaard A
PLoS Negl Trop Dis
. 2024 Nov;
18(11):e0012679.
PMID: 39591452
The rapid spread and growing number of dengue cases worldwide, alongside the absence of comprehensive vaccines and medications, highlights the critical need for robust tools to monitor, prevent, and control...
4.
Martinez-Vega R, Mbacham W, Ali I, Nji A, Mousa A, Beshir K, et al.
BMC Infect Dis
. 2024 Sep;
24(1):1028.
PMID: 39327613
Background: The World Health Organization 2022 malaria chemoprevention guidelines recommend providing a full course of antimalarial treatment at pre-defined intervals, regardless of malaria status to prevent illness among children resident...
5.
Bjorkman A, Gil P, Alifrangis M
Lancet Infect Dis
. 2024 Jul;
24(9):e540-e541.
PMID: 39053482
No abstract available.
6.
von Wowern F, Makenga G, Wellmann Thomsen S, Wellmann Thomsen L, Hocke E, Baraka V, et al.
Int J Infect Dis
. 2024 Jun;
146:107102.
PMID: 38876161
Objective: Intermittent Preventive Treatment of schoolchildren (IPTsc) is recommended by WHO as a strategy to protect against malaria; to explore whether IPTsc with dihydroartemisinin-piperaquine (DP) or artesunate-amodiaquine (ASAQ) cause a...
7.
Mousa A, Cuomo-Dannenburg G, Thompson H, Chico R, Beshir K, Sutherland C, et al.
PLoS Med
. 2024 May;
21(5):e1004376.
PMID: 38723040
Background: Recently revised WHO guidelines on malaria chemoprevention have opened the door to more tailored implementation. Countries face choices on whether to replace old drugs, target additional age groups, and...
8.
Toure M, Shaffer J, Sanogo D, Keita S, Keita M, Kane F, et al.
JMIR Res Protoc
. 2024 Jan;
13:e51660.
PMID: 38252481
Background: Seasonal malaria chemoprevention (SMC) is recommended by the World Health Organization for the sub-Sahel region in sub-Saharan Africa for preventing malaria in children 3 months old to younger than...
9.
Kajeguka D, Mponela F, Mkumbo E, Kaaya A, Lasway D, Kaaya R, et al.
J Trop Med
. 2023 Nov;
2023:5576300.
PMID: 38028027
Dengue virus is among the most important re-emerging arbovirus that causes global public health attention. Dengue has historically been thought of as an urban disease that frequently occurs in rapidly...
10.
Kahunu G, Wellmann Thomsen S, Wellmann Thomsen L, Muhindo Mavoko H, Mitashi Mulopo P, Hocke E, et al.
Int J Infect Dis
. 2023 Nov;
139:41-49.
PMID: 38016502
Objectives: Partial artemisinin resistance, mediated by Plasmodium falciparum K13 (PfK13) mutations, has been confirmed in certain areas of East Africa that are historically associated with high-level antimalarial resistance. The Democratic...